MLchartDataset catalogue

retifanlimab

Term · Oncology and biomedicine · MLC-T-ONC-007393

A drug used to treat adults with Merkel cell carcinoma (a type of skin cancer) that has come back or has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Retifanlimab binds to a protein called PD-1, which is found on T cells (a type of immune cell). Retifanlimab may block PD-1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Zynyz.

Table 1. Record
IdentifierMLC-T-ONC-007393
FieldOncology and biomedicine
SynonymsZynyz
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-007393",
  "term": "retifanlimab",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat adults with Merkel cell carcinoma (a type of skin cancer) that has come back or has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Retifanlimab binds to a protein called PD-1, which is found on T cells (a type of immune cell). Retifanlimab may block PD-1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Zynyz.",
  "synonyms": [
    "Zynyz"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/retifanlimab/"
}

Record 14,396 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.